195875-84-4

195875-84-4 structure

Name: Tesofensine
Chemical Name: (1R,2R,3S,5S)-3-(3,4-Dichlorophenyl)-2-(ethoxymethyl)-8-methyl-8- azabicyclo[3.2.1]octane
CAS Number: 195875-84-4
Molecular Formula: C₁₇H₂₃Cl₂NO
Molecular Weight: 328.27700
Catalog: Signaling Pathways Neuronal Signaling Dopamine Transporter
Create Date: 2016-02-13 20:56:45
Modify Date: 2024-01-02 19:14:54
Tesofensine (NS-2330) is a triple monoamine reuptake inhibitor inducing a potent inhibition of the re-uptake process in the synaptic cleft of the neurotransmitters dopamine (DA; IC50=6.5 nM), norepinephrine (NE;IC50=1.7 nM), and serotonin (5-HT;IC50=11 nM), and with potentials as an anti-obesity agent[1]. Tesofensine is a CNS acting anti-obesity agent[2].

Name	(1R,2R,3S,5S)-3-(3,4-Dichlorophenyl)-2-(ethoxymethyl)-8-methyl-8- azabicyclo[3.2.1]octane
Synonyms	Tesofensine

Description	Tesofensine (NS-2330) is a triple monoamine reuptake inhibitor inducing a potent inhibition of the re-uptake process in the synaptic cleft of the neurotransmitters dopamine (DA; IC50=6.5 nM), norepinephrine (NE;IC50=1.7 nM), and serotonin (5-HT;IC50=11 nM), and with potentials as an anti-obesity agent[1]. Tesofensine is a CNS acting anti-obesity agent[2].
Related Catalog	Research Areas >> Metabolic Disease Signaling Pathways >> Neuronal Signaling >> Dopamine Transporter Signaling Pathways >> Neuronal Signaling >> Serotonin Transporter
Target	DA/NE/5-HT[1]
In Vivo	Tesofensine (a single dose of 0.1-3 mg/kg, s.c.) induces hypophagia in the DIO rat. A single dose of Tesofensine (0. 1-3 mg/kg, s.c.) robustly and dose dependently inhibits food intake in DIO rats over the 12 h nocturnal observation period. Daily administration of a moderate dose of Tesofensine (2.0 mg/kg, s.c.) over 16 days triggers a significant reduction in body weight after 4 days of administration relative to vehicle-treated controls[3]. Animal Model: Diet-induced obesity (DIO) rat[3] Dosage: 0.1-3 mg/kg Administration: Administered subcutaneously (s.c.); a single dose (acute treatment) Result: The threshold dose for inhibition of total food intake was 1.0 mg/kg. The ED50 for inhibition of total food intake in DIO rats was estimated to be 1.3 mg/kg. Animal Model: Diet-induced obesity (DIO) rat[3] Dosage: 2.0 mg/kg Administration: Administered subcutaneously (s.c.) daily for over 16 days (chronic treatment) Result: The average relative decrease in the body weight of tesofensine-treated DIO rats over the entire treatment period was 8.6±1.4%. When comparing to vehicle controls, the relative weight loss with tesofensine was 13.8±1.4%.
References	[1]. Lieuwe Appel, et al. Tesofensine, a novel triple monoamine re-uptake inhibitor with anti-obesity effects: dopamine transporter occupancy as measured by PET. Eur Neuropsychopharmacol. 2014 Feb;24(2):251-61. [2]. Ann A Coulter, et al. Centrally Acting Agents for Obesity: Past, Present, and Future. Drugs. 2018 Jul;78(11):1113-1132. [3]. Anne Marie D Axel, et al. Tesofensine, a novel triple monoamine reuptake inhibitor, induces appetite suppression by indirect stimulation of alpha1 adrenoceptor and dopamine D1 receptor pathways in the diet-induced obese rat.Neuropsychopharmacology. 2010 Jun;35(7):1464-76.

Density	1.161 g/cm3
Boiling Point	396.6ºC at 760 mmHg
Molecular Formula	C₁₇H₂₃Cl₂NO
Molecular Weight	328.27700
Flash Point	193.7ºC
Exact Mass	327.11600
PSA	12.47000
LogP	4.53410

195875-84-4	402856-42-2
861205-83-6	190327-07-2
173667-94-2